Indeed, triple-negative breast cancers (TNBCs), which account for approximately 15% of all breast cancer patients, are negative for ER, PR, and HER2 and exhibit poor prognosis and limited treatment options relative to other breast cancer subtypes [18]. This evidence concerns the gene ESR1 and breast carcinoma.